Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, as Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders

This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.

Inclusion Criteria:

• patients with relapsed or refractory chronic lymphoproliferative disorders
• salvage treatment with bendamustine +/- rituximab
• age ≥ 18 years

Exclusion Criteria:

• previous treatment with bendamustine